Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BONSAI
2023-509131-12-01Phase 2Authorised
- Sponsor
- Hellenic Society of Hematology
- Start
- Feb 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of belantamab mafodotin in immune thrombocytopenia (ITP), sponsored by Hellenic Society of Hematology. Primary endpoint: Complete response rate / Partial response rate at 6 months. Planned start Feb 2025; status: authorised.
02
Drugs
belantamab mafodotin
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on 2023-509131-12-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509131-12-01.